ProCE Banner Activity

Case Studies Illustrating the Latest Insights on Treating Polycythemia Vera

Clinical Thought

Read this commentary by 2 experts discussing their approaches to 2 distinct cases of patients with polycythemia vera based on currently available evidence.

Released: February 13, 2023

Expiration: February 12, 2024

No longer available for credit.
Begin Activity

Share

Faculty

Raajit K. Rampal

Raajit K. Rampal, MD, PhD

Associate Member
Director
MPN and Rare Hematologic Malignancies Program
Director
Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Brady L. Stein

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Provided by

ProCE Banner

Supporters

Supported by educational grants from

GSK

Incyte Corporation

PharmaEssentia Corp

Disclosure

Raajit Rampal, MD, PhD: consultant: AbbVie, Blueprint, Celgene/Bristol-Myers Squibb, Constellation/MorphoSys, CTI, Galecto, Incyte, Karyopharm, PharmaEssentia, Servier, Sierra Oncology/GlaxoSmithKline, Sumitomo Dainippon Kartos, Zentails; researcher: Constellation Pharmaceuticals, Ryvu, Stemline Therapeutics, Zentalis.

Brady L. Stein, MD, MHS: consultant/advisor/speaker: PharmaEssentia.